Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor κb in women with postmenopausal osteoporosis

Menopause

Volumn 17, Issue 1, 2010, Pages 140-144

  Reyes García, Rebeca ^a   Muñoz Torres, Manuel ^a,b   García, D Fernández ^a   Mezquita Raya, Pedro ^c   García Salcedo, Jose Antonio ^a,b   De Dios Luna, Juan ^d  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b Plataforma Metabolismo Mineral y Óseo RETICEF   (Spain)

^c HOSPITAL TORRECÁRDENAS   (Spain)

^d UNIVERSITY OF GRANADA   (Spain)

Author keywords

Alendronate; Osteoprotegerin; Postmenopausal osteoporosis; Total receptor activator of nuclear factor JB

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; VITAMIN D;

ADULT; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL ARTICLE; COLLES FRACTURE; CONTROLLED STUDY; FEMALE; FEMUR NECK; HIP FRACTURE; HUMAN; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN BLOOD LEVEL; VERTEBRA FRACTURE;

AGED; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPROTEGERIN; RANK LIGAND;

EID: 74549164805     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181ac0cc1     Document Type: Article

References (26)

1. Eriksen EF, Melsen F, Sod E, Barton I, Chines A. Effects of long term risedronate on quality and bone turnover in women with postmenopausal osteoporosis. Bone 2002;31:620-625.
2. Rodan GA, Martin TJ. Role of osteoblasts in hormonal control of bone resorptionVa hypothesis. Calcif Tissue Int 1981;33:349-351.
3. Vitte C, Fleisch H, Guentler HL. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 1996;137:2324-2333.
4. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-JB ligand and osteoprotegerin in bone biology. J Mol Med 2001;79:243-253.
5. Simonet WS, Lacey DL, Dunstan DR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309-319.
6. Bekker PJ, Holloway D, Nakanishi A, Arrigi M, Leese PT, Dunstan CR. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001;16:348-360.
7. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008;93:2149-2157.
8. Kim YH, Kim GS, Jeong-Hwa B. Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression. Exp Mol Med 2002;34:145-151.
9. Pan B, Farrugia A, To LB, et al. The nitrogen-containing bisphospho-nate, zoledronic acid, influences RANKL expression in human osteo-blast-like cells by activating TNF-> converting enzyme (TACE). J Bone Miner Res 2004;1:147-154.
10. Valleala H, Mandelin J, Laasonen L, Koivula M, Risteli J, Konttinen Y. Effect of cyclical intermittent etidronate therapy on circulating osteo-protegerin levels in patients with rheumatoid arthritis. Eur J Endocrinol 2003;148:527-530.
11. Alvarez L, Peris P, Guanñabens N, et al. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. Arthritis Rheum 2003;48: 824-828.
12. Mossetti G, Rendina D, De Filippo G, et al. Interleukin 6 and osteo-protegerin system in Paget's disease of bone: relationship to risedronate treatment. Bone 2005;36:549-554.
13. Voskaridou E, Terpos E, Spina G, et al. Pamidronate is an affective treatment for osteoporosis in patients with A-thalassaemia. Br J Haematol 2003;123:730-737.
14. Dobnig H, Hofbauer LC, Viereck V, Obermayer-Pietsch B, Fahleitner-Pammer A. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos Int 2006;17:693-703.
15. Genant HK, Jergas M. Assessment of prevalent and incident vertebral fractures in osteoporosis research. Osteoporos Int 2003;14:S43-S55.
16. Mezquita-Raya P, de la Higuera M, Garcia DF, et al. The contribution of serum osteoprotegerin on bone mass and vertebral fractures in post-menopausal women. Osteoporos Int 2005;16:1368-1374.
17. Oh KW, Rhee EJ, Lee WY, et al. Circulating osteoprotegerin and receptor activator of NF-JB ligand system are associated with bone metabolism in middle aged males. Clin Endocrinol 2005;62:92-98.
18. Indridason OS, Franson L, Sigurdsson G. Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. Osteoporos Int 2005;16:417-423.
19. Fahrleitner-Pammer A, Dobnig H, Piswanger-Soelkner C, et al. Osteo-protegerin serum levels in women: correlation with age, bone mass, bone turnover or fracture status. Wien Klin Wochenschr 2003;115:291-297.
20. Rogers A, Saleh G, Hannon RA, Greenfield D, Eastell R. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab 2002; 87:4470-4475. (Pubitemid 35247027)
21. Browner WS, Lui LY, Cummings SR. Associations of serum osteopro-tegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001;86:631-637.
22. Rogers A, Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor JB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 2005;90:6323-6331.
23. Khosla S, Arrighi HM, Melton LJ, et al. Correlates of osteoprotegerin levels in women and men. Osteoporos Int 2002;13:394-399.
24. Zojer N, Brenner K, Kudlacek S, et al. Bisphosphonate treatment does not affect serum levels of osteoprotegerin and RANKL in hypercalcemic cancer patients. Anticancer Res 2005;25:3607-3612.
25. Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD. Osteopro-tegerin serum levels in men: correlation with age, estrogen and testosterone status. J Clin Endocrinol Metab 2001;86:3162-3165.
26. Schett G, Kiechl S, Redlich K, et al. Soluble RANKL and risk of nontraumatic fracture. JAMA 2004;291:1108-1113. (Pubitemid 38541688)